Table 1 Baseline characteristics of eligible patients
|  | BBP group (%) N = 37 | Non-BBP group (%) N = 25 | P-value |
|---|---|---|---|
Sex | |||
 Male | 19 (51.4) | 8 (32.0) | 0.192 |
 Female | 18 (48.6) | 17 (68.0) | |
Age (years) | |||
 Median (range) | 59 (34–82) | 57 (27–74) | 0.503 |
ECOG PS | |||
 0 | 12 (32.4) | 7 (28.0) | 0.010 |
 1 | 21 (56.8) | 7 (28.0) | |
 2≤ | 3 (8.1) | 10 (40.0) | |
 Unknown | 1 (2.7) | 1 (4.0) | |
RAS status | |||
 KRAS/RAS wild type | 11 (32.4) | 19 (76.0) | 0.001 |
 KRAS/RAS mutant | 20 (54.0) | 4 (16.0) | |
 Unknown | 6 (16.2) | 2 (8.0) | |
Primary location | |||
 Right sidea | 16 (43.2) | 10 (40.0) | 1.000 |
 Left sideb | 21 (56.8) | 15 (60.0) | |
Disease status | |||
 Stage IV | 24 (64.9) | 21 (84.0) | 0.147 |
 Recurrence | 13 (35.1) | 4 (16.0) | |
Number of metastatic organ sites | |||
 1 | 13 (35.1) | 5 (20.0) | 0.259 |
 2≤ | 24 (64.9) | 20 (80.0) | |
Metastatic sites | |||
 Liver | 32 (86.5) | 18 (72.0) | 0.198 |
 Lung | 14 (37.8) | 9 (36.0) | 1.000 |
 Lymph node | 13 (35.1) | 12 (48.0) | 0.429 |
 Peritoneum | 8 (21.6) | 12 (48.0) | 0.051 |
First-line chemotherapy | |||
 Oxaliplatin-based regimen | 31 (83.8) | 24 (96.0) | 0.225 |
 Irinotecan-based regimen | 6 (16.2) | 1 (4.0) | |